GENENTECH TO BEGIN SHIPPING PULMOZYME JAN. 12; ANNUAL TREATMENT COST IS $9,855 TO WHOLESALERS: FIRM ESTABLISHES "ENDOWMENT" FOR INDIGENT PATIENTS
Executive Summary
Genentech will begin shipping the cystic fibrosis treatment Pulmozyme (dornase alfa) Jan. 12, within two weeks of FDA approval of the product Dec. 30. In a Jan. 6 letter addressed to "CF Caregivers," Genentech told physicians that "your patients should be able to obtain Pulmozyme commercially by the end of next week."